SMT201600134B - Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak. - Google Patents
Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak.Info
- Publication number
- SMT201600134B SMT201600134B SM201600134T SM201600134T SMT201600134B SM T201600134 B SMT201600134 B SM T201600134B SM 201600134 T SM201600134 T SM 201600134T SM 201600134 T SM201600134 T SM 201600134T SM T201600134 B SMT201600134 B SM T201600134B
- Authority
- SM
- San Marino
- Prior art keywords
- diamminopyrimidine
- molted
- fak
- alk
- double inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607305P | 2012-03-06 | 2012-03-06 | |
| PCT/US2013/029304 WO2013134353A1 (en) | 2012-03-06 | 2013-03-06 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201600134B true SMT201600134B (it) | 2016-07-01 |
Family
ID=47892060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201600134T SMT201600134B (it) | 2012-03-06 | 2016-05-10 | Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak. |
Country Status (28)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA033124B1 (ru) * | 2012-03-06 | 2019-08-30 | Сефалон, Инк. | Применение конденсированного бициклического 2,4-диаминопиримидинового производного для лечения alk- или fak-опосредованного заболевания или нарушения у субъекта |
| SG11201608303QA (en) | 2014-04-04 | 2016-11-29 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
| JP6849594B2 (ja) * | 2014-12-23 | 2021-03-24 | セファロン、インク． | 縮合二環式２，４−ジアミノピリミジン誘導体を調整する方法 |
| CA3108236A1 (en) | 2018-08-07 | 2020-02-13 | In3Bio Ltd. | Methods and compositions for inhibition of egf/egfr pathway in combination with anaplastic lymphoma kinase inhibitors |
| WO2024178339A2 (en) * | 2023-02-23 | 2024-08-29 | The Regents Of The University Of Michigan | Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2532800C (en) | 2003-07-23 | 2013-06-18 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| SI2287156T1 (sl) | 2003-08-15 | 2013-09-30 | Novartis Ag | 2,4-di(fenilamino)-pirimidini, uporabni pri zdravljenju neoplastičnih bolezni, vnetnih motenj in motenj imunskega sistema |
| JP4989233B2 (ja) * | 2004-02-14 | 2012-08-01 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| WO2005097765A1 (en) | 2004-03-31 | 2005-10-20 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| WO2007098507A2 (en) * | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| NZ576425A (en) * | 2006-10-23 | 2012-04-27 | Cephalon Inc | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors |
| EP2311807B1 (en) * | 2006-12-08 | 2015-11-11 | Novartis AG | Compounds and composition as protein kinase inhibitors |
| JP4782239B2 (ja) * | 2007-04-18 | 2011-09-28 | ファイザー・プロダクツ・インク | 異常細胞増殖治療のためのスルホニルアミド誘導体 |
| HUE028278T2 (en) * | 2009-06-10 | 2016-12-28 | Chugai Pharmaceutical Co Ltd | Tetracyclic compound |
| EA033124B1 (ru) * | 2012-03-06 | 2019-08-30 | Сефалон, Инк. | Применение конденсированного бициклического 2,4-диаминопиримидинового производного для лечения alk- или fak-опосредованного заболевания или нарушения у субъекта |
| KR101446742B1 (ko) * | 2012-08-10 | 2014-10-01 | 한국화학연구원 | Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| JP6849594B2 (ja) * | 2014-12-23 | 2021-03-24 | セファロン、インク． | 縮合二環式２，４−ジアミノピリミジン誘導体を調整する方法 |
-
2013
- 2013-03-06 EA EA201691574A patent/EA033124B1/ru not_active IP Right Cessation
- 2013-03-06 ES ES13710258T patent/ES2570976T3/es active Active
- 2013-03-06 EA EA201491641A patent/EA025859B1/ru not_active IP Right Cessation
- 2013-03-06 MX MX2014010613A patent/MX347772B/es active IP Right Grant
- 2013-03-06 MY MYPI2014002428A patent/MY177290A/en unknown
- 2013-03-06 WO PCT/US2013/029304 patent/WO2013134353A1/en not_active Ceased
- 2013-03-06 AU AU2013229995A patent/AU2013229995B2/en active Active
- 2013-03-06 SG SG11201405371PA patent/SG11201405371PA/en unknown
- 2013-03-06 RS RS20160238A patent/RS54689B1/sr unknown
- 2013-03-06 EP EP13710258.8A patent/EP2822939B1/en active Active
- 2013-03-06 ES ES15202516.9T patent/ES2681487T3/es active Active
- 2013-03-06 CN CN201610591742.5A patent/CN106166155B/zh active Active
- 2013-03-06 EP EP15202516.9A patent/EP3056494B1/en active Active
- 2013-03-06 JP JP2014561069A patent/JP6016953B2/ja not_active Expired - Fee Related
- 2013-03-06 NZ NZ630251A patent/NZ630251A/en unknown
- 2013-03-06 SI SI201330151T patent/SI2822939T1/sl unknown
- 2013-03-06 HU HUE13710258A patent/HUE027976T2/en unknown
- 2013-03-06 SG SG10201507865QA patent/SG10201507865QA/en unknown
- 2013-03-06 UA UAA201410832A patent/UA115052C2/uk unknown
- 2013-03-06 MX MX2017006206A patent/MX372740B/es unknown
- 2013-03-06 CA CA2865420A patent/CA2865420C/en active Active
- 2013-03-06 PL PL13710258T patent/PL2822939T3/pl unknown
- 2013-03-06 HR HRP20160387TT patent/HRP20160387T1/hr unknown
- 2013-03-06 ME MEP-2016-68A patent/ME02460B/me unknown
- 2013-03-06 CN CN201380012764.6A patent/CN104159894B/zh active Active
- 2013-03-06 KR KR1020147027590A patent/KR102068374B1/ko active Active
- 2013-03-06 DK DK13710258.8T patent/DK2822939T3/en active
-
2014
- 2014-08-21 IL IL234239A patent/IL234239A/en active IP Right Grant
- 2014-08-21 ZA ZA2014/06147A patent/ZA201406147B/en unknown
- 2014-09-02 US US14/474,928 patent/US9132128B2/en active Active
- 2014-09-05 CL CL2014002353A patent/CL2014002353A1/es unknown
- 2014-09-05 PH PH12014501979A patent/PH12014501979A1/en unknown
-
2015
- 2015-08-12 US US14/824,750 patent/US9339502B2/en active Active
-
2016
- 2016-05-04 US US15/146,164 patent/US9623026B2/en not_active Expired - Fee Related
- 2016-05-10 SM SM201600134T patent/SMT201600134B/it unknown
- 2016-05-10 CY CY20161100390T patent/CY1117565T1/el unknown
- 2016-09-27 JP JP2016188585A patent/JP2017039741A/ja active Pending
-
2017
- 2017-03-07 US US15/451,960 patent/US10111872B2/en active Active
- 2017-05-18 IL IL252364A patent/IL252364B/en active IP Right Grant
-
2018
- 2018-10-26 US US16/172,368 patent/US10632119B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201600134B (it) | Derivato biciclico fuso di 2, 4-diamminopirimidina come un inibitore doppio di alk e fak. | |
| SMT201700052B (it) | 2-(azaindol-2-il)benzimidazoli come inibitori di pad4 | |
| DK3071203T3 (da) | Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer | |
| HUE036259T2 (hu) | Inhibitor vegyületek | |
| SI3715345T1 (sl) | Priprava zaviralca lfa-1 | |
| DK3181567T5 (da) | Pyrazolopyrimidinforbindelser som kinasehæmmere | |
| DK2920149T3 (da) | 3-aminocycloalkyl-forbindelser som ror-gamma-t-inhibitorer og anvendelser deraf | |
| LT3702351T (lt) | Kompozicijos, apimančios mek inhibitorių | |
| SMT201600114B (it) | Inibitori di beta-secretasi | |
| WO2014047502A3 (en) | Anhydrous compositions having microcapsules and non-volatile oils | |
| DK2804858T3 (da) | Metalloenzym-inhibitorforbindelser | |
| EP2840076A4 (en) | BICYCLIC CONNECTION | |
| EP2863748A4 (en) | 1,2,4-triazine-6-CARBOXAMIDKINASEINHIBITOREN | |
| BR112014007719A2 (pt) | proteases fúngicas | |
| ME02985B (me) | Prolekovi inhibitora amino-hinazolinske kinaze | |
| EP2933248A4 (en) | NOVEL RENIN INHIBITOR | |
| SMT201600357B (it) | Inibitori di iap | |
| DK2934510T3 (da) | Lfa-1-inhibitorformuleringer | |
| EP3082822A4 (en) | Hiv protease inhibitors | |
| EP3083609A4 (en) | Hiv protease inhibitors | |
| ITTO20110857A1 (it) | Procedimento per la produzione di cicloesanonossina. | |
| EP2875885A4 (en) | Novel drill chuck | |
| FR2959588B1 (fr) | Condensateur auto-protege. | |
| FR2991112B1 (fr) | Laser semiconducteur optimise | |
| DE102010048360A8 (de) | Laserzünder |